Skip to main content
SP5007,754.28-0.40%DOW53,452.77-0.52%NASDAQ26,638.99-0.34%BTC$64,269.00+1.84%ETH$1,906.18+1.19%GOLD$4,471.90+0.78%OIL$84.65+2.73%
Smart Investors Daily
Sign InSign Up Free
RA

OTC · RAPH

Raphael Pharmaceutical Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$1.40

Up+$0.00 (+0.00%)

Updated Aug 17, 2026, 6:10 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
27.48M
P/E ratio
-18.67
Dividend yield
0.00%
52-week range
— – —
Volume
140
Avg. volume
14

Price performance

RAPH price history

1M range · 0 trading sessions · Daily adjusted prices

RAPH does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RAPH news

The latest Smart Investors Daily articles mentioning RAPH.

Stock researchCompany · Overview

RAPH research

Overview

Company profile and research snapshot.

Company profile

RAPHAEL PHARMACEUTICL INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 17, 2025

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative research platform based on cannabinoids free of THC and CBD, today announced the filing of a provisional patent application with the United States Patent and Trademark Office. The application covers the use of the Company’s highly purified cannabinoid-based technology platform in the treatment of neutrop

globenewswire.com · Nov 17, 2025

Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative research platform based on cannabinoids free of THC and CBD, today announced the filing of a provisional patent application with the United States Patent and Trademark Office.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By